A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
Quantara AI launches a continuous platform designed to estimate the financial impact of cyber risk as companies move beyond periodic assessments
Updated
March 17, 2026 1:02 AM
A person tightrope walking between two cliffs. PHOTO: UNSPLASH
Cyber risk is increasingly treated as a financial issue. Boards want to know how much a cyber incident could cost the company, how it could affect earnings, and whether current security spending is justified.
Yet many organizations still measure cyber risk through periodic reviews. These assessments are often conducted once or twice a year, supported by consultants and spreadsheet models. By the time the report reaches senior leadership, the company’s systems may have changed and new threats may have emerged. The way risk is measured does not always match how quickly it evolves.
This gap is where Quantara AI is positioning its new platform. Quantara AI, a Boise-based cybersecurity startup, has introduced what it describes as the industry’s first persistent AI-powered cyber risk solution. The system is designed to run continuously rather than rely on occasional assessments.
The company’s core argument is straightforward: not every security weakness carries the same financial consequence. Instead of ranking issues only by technical severity, the platform analyzes active threats, identifies which company systems are exposed, and estimates how much money a successful attack could cost. It uses statistical models, including Value at Risk (VaR), to calculate potential losses. It also estimates how specific security improvements could reduce that projected loss.
The timing aligns with a broader market shift. International Data Corporation (IDC) projects that by 2028, 40% of enterprises will adopt AI-based cyber risk quantification platforms. These tools convert security data into financial estimates that can guide budgeting and investment decisions. The forecast reflects growing pressure on security leaders to present risk in terms that boards and regulators understand.
Traditional compliance and risk management systems often focus on meeting regulatory standards. Vulnerability management programs typically score weaknesses based on technical characteristics. Consultant-led risk studies provide detailed analysis, but they are usually performed at set intervals. In fast-changing threat environments, that model can leave decision-makers working with outdated information.
Quantara’s platform attempts to replace that periodic process with continuous measurement. It brings together threat data, internal system information and financial modeling in one system. The goal is to show, at any given time, which specific weaknesses could lead to the largest financial losses.
Cyber risk quantification as a concept is not new. What is changing is the expectation that these calculations be updated regularly and tied directly to financial decision-making. As cyber incidents carry clearer monetary consequences, companies are looking for ways to measure exposure with greater precision.
The broader question is whether enterprises will shift fully toward continuous, AI-driven risk analysis or continue relying on periodic external assessments. What is clear is that cybersecurity discussions are moving closer to financial reporting — and tools that estimate potential loss in dollar terms are becoming central to that shift.